Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Osimertinib plus durvalumab versus osimertinib alone in EGFR T790M-positive advanced non-small cell lung cancer after prior EGFR TKI
jRCT2080222938Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Aug 2015
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in non-small cell lung cancer (NSCLC) comparing Osimertinib + durvalumab with Osimertinib monotherapy (2 arms). Started Aug 2015; status: completed.
02
Drugs
osimertinibdurvalumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT2080222938.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222938.